Possible Role of Osteoprotegerin and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand as Markers of Plaque Instability in Coronary Artery Disease

Angiology

Volumn 61, Issue 8, 2010, Pages 756-762

  Shaker, Olfat G ^a   el Shehaby, Amal ^a   Nabih, Mona ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

acute myocardial infarction; coronary artery disease; osteoprotegerin; tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

BIOLOGICAL MARKER; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ARTICLE; BLOOD; CORONARY ARTERY DISEASE; HEART INFARCTION; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OSTEOPROTEGERIN; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 78049444200     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319710370961     Document Type: Article

References (36)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340(2):115-126.
2. Glass CK, Witztum JL. The road ahead. Atherosclerosis. 2001; 104(4):503-516.
3. Libby P. Inflammation in atherosclerosis. Nature. 2002;26: 420(6917):868-874.
4. Hansson GK, Libby P, Schonbeck U. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res. 2002;91(4):281-291.
5. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91(11):2844-2850.
6. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001;104(3):365-372.
7. Bucay N, Sarosi I, Dunstan CR. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Gene Dev. 1998;12(9):1260-1268.
8. Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998; 273(23):14363-14367.
9. Pritzker LB, Scatena M, Giachelli CM. The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. Mol Cell Biol. 2004;15(6):2834-2841.
10. Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAILinduced apoptosis by a family of signaling and decoy receptors. Science. 1997;277(5327):818-821.
11. Sprick MR, Weigand MA, Rieser E, et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 are essential for apoptosis mediated by TRAIL receptor 2. Immunity. 2000; 12(6):599-609.
12. Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNFfamily death receptors. Oncogene. 2003;22(53):8628-8633.
13. Jo M, Kirn TH, Seol DW, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosisinducing ligand. Nat Med. 2000;6(5):564-567.
14. Criteria committee of New York Heart Association. Diseases of the heart and blood vessels: nomenclature and criteria for diagnosis. Boston, MA: Little, Brown and Company Inc; 1964:114.
15. Yano K, Tsuda E, Washida N, et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res. 1999;14(4):518-527.
16. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and Osteoprotegerin. Paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol. 2002;22(4): 549-553.
17. Dhore CR, Cleutjens JP, Lutgens E. Differential expression of bone matrix regulatory proteins inhuman atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2003;21(12):1998-2003.
18. Jono S, Ikari Y, Shioi A. Serum Osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation. 2002;106(10):1192-1194.
19. Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B. Hofbauer LC. Increased Osteoprotegerin serum levels in men with coronary artery disease. Clin Endocrinol Metab. 2003; 88(3):1024-1028.
20. Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004;109(18):2175-2180.
21. Crisafulli A, Micari A, Altavilla D, et al. Serum levels of Osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin Sci. 2005;109(4):389-395.
22. Wexler L, Brundage F, Crouse J, et al. Coronary artery calcification: pathophysiology, epidemiology and clinical implications. Circulation. 1996;94(5):1175-1192.
23. Leho S, Niskanen L, Suhonen M, Ronnemaa T, Laakso M. A neglected harbinger of cardiovascular complication in NIDDM. Arterioscler. Thromb Vasc Biol. 1996;16(8):978-983.
24. Min H, Morroni S, Sarrosi I. Osteoprotegrin reverses osteoporsis by inhibiting osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med. 2000;192(4):463-474.
25. Collin-Osdoby P, Rothe L, Anderson E, Nelson M, Maloney W, Osdoby P. Receptor activator of NF-kb and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem. 2001;276(23):20659-20672.
26. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135-1143.
27. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA. 2004;292(4):490-495.
28. Paoletti R, Gotto AM Jr, Hajjar DP. Inflammation in atherosclerosis and implications for therapy. Circulation. 2004; 109(23 suppl 1):20-26.
29. Labarrere CA, Zaloga GP. C-reactive protein: from innocent bystander to pivotal mediator of atherosclerosis. Am J Med. 2004;117(7):499-507.
30. Rhee EJ, Lee WY, Kim SY, et al. Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. Clin Sci. 2005;108(3): 237-243.
31. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 2001;86(2):631-637.
32. Sato K, Niessner A, Stephen LK, Frye RL, Weyand CM. TRAIL expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque. JEM. 2006;203(1):239-250.
33. Hanasson GK, Holm J, Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaques. Am J Pathol. 1989;135(1):169-175.
34. Schoppet M, Sattler AM, Schaefer JR, Hofbauer LC. Osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand levels in atherosclerosis. Atherosclerosis. 2006;184(2): 446-447.
35. Michowitz Y, Goldstein E, Roth A, et al. The involvement of tumor necrosis factor-related apoptosis-inducing ligand in atherosclerosis. J Am Coll Cardiol. 2005;45(7):1018-1024.
36. Secchiero P, Corallini F, Beltrami AP, et al. An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. Atherosclerosis. 2009 Nov 10. [Epub ahead of print].